The Latest Cardiac and Vascular News
ENGLEWOOD, Colo., Oct. 23, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Neil Friery as the President and Chief Operating Officer (COO) of its Monitoring Solutions Division. As […]
MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu […]
Patrick Kaltenbach appointed chief technology officer Dave Hickey promoted to president, Life Sciences segment FRANKLIN LAKES, N.J., Oct. 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of Dave Hickey to executive vice […]
RED DESERT: Results from first five patients indicaterepeated dose alfapump DSR therapy to be safeandeffective Interim data support DSR hypothesis: kidneys eliminate free water to maintain patients’ serum sodium levels No patients required loop diuretic therapy during the six-week alfapump DSR treatment period Followingalfapump DSR treatment, loop diuretic responsiveness was restored to near normal levels; effect was durable for months post-treatmentwith majority of patients requiring little or no diuretic therapy Full RED DESERT data on track […]
IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights and Outlook Sales of $1.1 billion grew 4%; similar underlying1 growth expected in the fourth quarter TAVR global sales grew 6% EPS was $0.52; adjusted1 EPS grew 9% to $0.51 TMTT clinical trials now enrolling […]
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association Scientific Sessions 2020; Pivotal Phase 3 Study Planned for Initiation in H1 2021 SAN FRANCISCO, Oct. 21, 2020 (GLOBE NEWSWIRE) — InCarda Therapeutics, […]
– Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent – Sales growth in Medical Devices and Diagnostics improved significantly versus prior quarter – Continues to strengthen portfolio with several recent new product approvals, including FreeStyle Libre 3, Libre Sense Glucose Sport Biosensor and MitraClip G4 heart […]
Real-world findings helped in decision making to remove drug’s prior authorization EAGAN, Minn., Oct. 20, 2020 /PRNewswire/ — Sacubitril-valsartan (Entresto®) has been proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF) also known as systolic heart failure. 1 According to a recent study by Prime Therapeutics LLC […]
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) — via NewMediaWire ‒ Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, today announced the appointment of Stuart Bernstein as Vice President of Marketing. In this role, Bernstein will be responsible for Brain Scientific’s overall marketing strategy and efforts to strengthen the company’s market […]
Uses Cash to Pay Down Debt PLANO, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) — Integer Holdings Corporation (“Integer”) (NYSE: ITGR), a leading medical device outsource manufacturer, received approximately $28 million following the Federal Court of Appeals for the Federal Circuit affirming, in all respects, the ruling in Integer’s favor granted […]
